

Table 4.24

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	243,134	99.4%	202,283	99.4%	21,929	99.3%	16,291	99.3%	845	98.8%	21,806	99.1%
Epidermoid carcinoma ^d (8051-8131)	174	0.1%	134	0.1%	31	0.1%	-	-	-	-	-	-
Adenocarcinoma ^e	237,448	97.1%	197,895	97.3%	21,027	95.2%	15,983	97.4%	828	96.8%	21,134	96.0%
Adenocarcinoma, NOS (8140)	2,446	1.0%	1,973	1.0%	307	1.4%	119	0.7%	-	-	227	1.0%
Infiltrating duct carcinoma (8500)	167,100	68.3%	137,352	67.5%	15,766	71.4%	12,160	74.1%	621	72.6%	15,326	69.6%
Lobular carcinoma, NOS (8520)	19,613	8.0%	17,469	8.6%	1,226	5.6%	734	4.5%	58	6.8%	1,419	6.4%
Inflammatory adenocarcinoma (8530)	2,042	0.8%	1,668	0.8%	272	1.2%	87	0.5%	-	-	282	1.3%
Infiltrating duct mixed and infiltrating lobular mixed (8522-8524)	29,956	12.2%	25,960	12.8%	2,055	9.3%	1,644	10.0%	94	11.0%	2,514	11.4%
Mucinous adenocarcinoma (8480,8482)	6,147	2.5%	5,029	2.5%	506	2.3%	545	3.3%	20	2.3%	479	2.2%
Mucin-producing adenocarcinoma (8481)	133	0.1%	110	0.1%	17	0.1%	-	-	-	-	-	-
Tubular adenocarcinoma (8211)	3,547	1.5%	3,231	1.6%	138	0.6%	133	0.8%	-	-	191	0.9%
Papillary adenocarcinoma (8050,8260,8503,8504)	1,435	0.6%	1,035	0.5%	222	1.0%	156	1.0%	-	-	160	0.7%
Paget disease (8540-8543)	1,396	0.6%	1,159	0.6%	127	0.6%	102	0.6%	-	-	160	0.7%
Other adenocarcinomas ^f	3,633	1.5%	2,909	1.4%	391	1.8%	298	1.8%	-	-	369	1.7%
Other specific carcinomas ^g	2,735	1.1%	2,040	1.0%	512	2.3%	160	1.0%	-	-	354	1.6%
Medullary adenocarcinoma (8510-8513)	1,527	0.6%	1,071	0.5%	340	1.5%	103	0.6%	-	-	236	1.1%
Other ^h	1,208	0.5%	969	0.5%	172	0.8%	57	0.3%	-	-	118	0.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	2,777	1.1%	2,214	1.1%	359	1.6%	142	0.9%	-	-	303	1.4%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

ⁱ Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.24 - continued

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	307	0.1%	253	0.1%	28	0.1%	18	0.1%	-	-	20	0.1%
Hemangiosarcomas (9120-9126,9170)	144	0.1%	129	0.1%	-	-	-	-	-	-	-	-
Other sarcomas ^d	163	0.1%	124	0.1%	21	0.1%	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	678	0.3%	510	0.3%	71	0.3%	82	0.5%	-	-	116	0.5%
Phyllodes tumor, malignant (9020)	553	0.2%	417	0.2%	53	0.2%	71	0.4%	-	-	98	0.4%
Other ^e	125	0.1%	93	0.0%	18	0.1%	-	-	-	-	18	0.1%
Unspecified (8000-8005)	468	0.2%	363	0.2%	55	0.2%	23	0.1%	-	-	68	0.3%
Total ^f	244,587	100.0%	203,409	100.0%	22,083	100.0%	16,414	100.0%	855	100.0%	22,010	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

^e Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

^f Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.25

Cancer of the Female Breast(*In Situ*)Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	56,033	95.0%	45,834	94.9%	4,837	95.7%	4,548	94.7%	163	96.4%	4,577	95.6%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Cribriform carcinoma <i>in situ</i> (8201/2)	4,737	8.0%	3,816	7.9%	370	7.3%	492	10.2%	-	-	389	8.1%
Ductal carcinoma <i>in situ</i> (8500/2)	20,472	34.7%	16,715	34.6%	1,819	36.0%	1,645	34.3%	72	42.6%	1,648	34.4%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	6,786	11.5%	5,950	12.3%	408	8.1%	240	5.0%	23	13.6%	496	10.4%
Comedocarcinoma <i>in situ</i> (8501/2)	4,746	8.0%	3,934	8.1%	392	7.8%	372	7.7%	-	-	378	7.9%
Intraductal and lobular carcinoma <i>in situ</i> (8522/2,8523/2,8524/2)	15,358	26.0%	12,336	25.6%	1,405	27.8%	1,459	30.4%	31	18.3%	1,329	27.8%
Intraductal micropapillary (8507/2)	1,734	2.9%	1,412	2.9%	177	3.5%	123	2.6%	-	-	154	3.2%
Other adenocarcinomas ^e	2,185	3.7%	1,657	3.4%	266	5.3%	216	4.5%	-	-	183	3.8%
Other <i>in situ</i> histologies ^f	2,941	5.0%	2,444	5.1%	219	4.3%	253	5.3%	-	-	209	4.4%
Total	58,974	100.0%	48,278	100.0%	5,056	100.0%	4,801	100.0%	169	100.0%	4,786	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8490, 8502-8506, 8514, 8521, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.15

Cancer of the Cervix Uteri (Invasive)Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	15,531	98.4%	11,846	98.4%	2,015	98.3%	1,388	98.5%	88	100.0%	3,684	99.0%
Epidermoid carcinoma ^d (8050-8131)	10,835	68.7%	8,114	67.4%	1,608	78.5%	914	64.9%	69	78.4%	2,697	72.5%
Squamous cell carcinoma (8070)	7,026	44.5%	5,184	43.1%	1,154	56.3%	564	40.0%	43	48.9%	1,578	42.4%
Squamous cell, keratinizing (8071)	1,217	7.7%	925	7.7%	174	8.5%	97	6.9%	-	-	381	10.2%
Squamous cell, non-keratinizing (8072)	1,504	9.5%	1,174	9.8%	166	8.1%	143	10.1%	-	-	429	11.5%
Squamous cell, Microinvasive (8076)	846	5.4%	662	5.5%	80	3.9%	76	5.4%	-	-	247	6.6%
Other (8050-8069, 8073-8075,8077-8131)	242	1.5%	169	1.4%	34	1.7%	34	2.4%	-	-	62	1.7%
Adenocarcinoma (8140-8147,8160-8162, 8180-8221,8250-8507,8514, 8520-8551,8560,8570-8574, 8576,8940-8941)	3,976	25.2%	3,201	26.6%	304	14.8%	403	28.6%	-	-	839	22.5%
Adenocarcinoma, NOS (8140)	2,078	13.2%	1,684	14.0%	151	7.4%	203	14.4%	-	-	442	11.9%
Adenosquamous (8560,8570)	678	4.3%	535	4.4%	67	3.3%	70	5.0%	-	-	179	4.8%
Other adenocarcinomas (8141-8147,8160-8162, 8180-8221,8250-8507, 8514,8520-8551, 8571-8574,8576, 8940-8941)	1,220	7.7%	982	8.2%	86	4.2%	130	9.2%	-	-	218	5.9%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	263	1.7%	193	1.6%	28	1.4%	38	2.7%	-	-	54	1.5%
Unspecified, Carcinoma, NOS (8010-8011)	457	2.9%	338	2.8%	75	3.7%	33	2.3%	-	-	94	2.5%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.15 - continued

Cancer of the Cervix Uteri (Invasive)Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Females by Race

Histology ^a	<u>All Races</u>		<u>White</u>		<u>Black</u>		<u>Asian/Pacific Islander</u>		<u>American Indian/ Alaska Native^b</u>		<u>Hispanic^c</u>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	69	0.4%	57	0.5%	-	-	-	-	-	-	16	0.4%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	122	0.8%	90	0.7%	17	0.8%	-	-	-	-	-	-
Unspecified (8000-8005)	59	0.4%	42	0.3%	-	-	-	-	-	-	-	-
Total ^d	15,781	100.0%	12,035	100.0%	2,049	100.0%	1,409	100.0%	88	100.0%	3,722	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.26

Cancer of the Colon And Rectum (Invasive)Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	172,407	99.5%	140,950	99.5%	17,317	99.5%	11,977	99.6%	761	99.0%	14,527	99.5%
Epidermoid carcinoma ^d (8051-8131)	718	0.4%	605	0.4%	88	0.5%	-	-	-	-	73	0.5%
Squamous cell carcinoma (8070-8078,8083-8084)	651	0.4%	546	0.4%	83	0.5%	-	-	-	-	64	0.4%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8520-8551,8560, 8570-8574,8576,8940-8941)	164,141	94.8%	134,904	95.3%	16,130	92.7%	11,294	93.9%	700	91.0%	13,602	93.1%
Adenocarcinoma, NOS (8140)	113,323	65.4%	92,843	65.6%	11,258	64.7%	8,110	67.4%	527	68.5%	9,339	64.0%
Adenocarcinoma in adenomatous polyp (8210)	11,108	6.4%	9,033	6.4%	955	5.5%	883	7.3%	49	6.4%	845	5.8%
Adenocarcinoma in villous adenoma (8261)	5,546	3.2%	4,589	3.2%	558	3.2%	332	2.8%	-	-	548	3.8%
Mucinous adenocarcinoma (8470-8473,8480,8482)	13,213	7.6%	11,196	7.9%	1,177	6.8%	735	6.1%	51	6.6%	1,179	8.1%
Mucin-producing adenocarcinoma (8481)	4,345	2.5%	3,548	2.5%	557	3.2%	212	1.8%	-	-	338	2.3%
Signet ring adenocarcinoma (8490)	2,047	1.2%	1,739	1.2%	156	0.9%	138	1.1%	-	-	178	1.2%
Other adenocarcinomas ^e	14,559	8.4%	11,956	8.4%	1,469	8.4%	884	7.3%	43	5.6%	1,175	8.0%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	5,919	3.4%	4,108	2.9%	927	5.3%	575	4.8%	50	6.5%	693	4.7%
Neuroendocrine carcinoid (8240-8245)	4,986	2.9%	3,324	2.3%	843	4.8%	523	4.3%	45	5.9%	613	4.2%
Other ^f	933	0.5%	784	0.6%	84	0.5%	52	0.4%	-	-	80	0.5%
Unspecified, Carcinoma, NOS (8010-8011, 8020-8022)	1,629	0.9%	1,333	0.9%	172	1.0%	98	0.8%	-	-	159	1.1%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.26 - continued

Cancer of the Colon And Rectum (Invasive)Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	94	0.1%	73	0.1%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	216	0.1%	168	0.1%	23	0.1%	23	0.2%	-	-	18	0.1%
Unspecified (8000-8005)	513	0.3%	427	0.3%	50	0.3%	22	0.2%	-	-	48	0.3%
Total ^d	173,230	100.0%	141,618	100.0%	17,401	100.0%	12,029	100.0%	769	100.0%	14,603	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 8.19

Cancer of the Esophagus (Invasive)Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	15,606	99.1%	13,096	99.1%	1,658	99.5%	695	99.0%	71	100.0%	1,017	98.7%
Epidermoid carcinoma ^d (8051-8131)	5,785	36.7%	3,847	29.1%	1,373	82.4%	501	71.4%	39	54.9%	447	43.4%
Squamous cell carcinoma (8070-8078, 8083-8084)	5,767	36.6%	3,831	29.0%	1,372	82.4%	500	71.2%	39	54.9%	445	43.2%
Adenocarcinoma (8050,8140-8147,8160-8162, 8180-8221,8250-8507,8514, 8520-8551,8560,8570-8574, 8576,8940-8941)	8,913	56.6%	8,473	64.1%	205	12.3%	158	22.5%	26	36.6%	518	50.3%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	265	1.7%	225	1.7%	19	1.1%	-	-	-	-	16	1.6%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	643	4.1%	551	4.2%	61	3.7%	21	3.0%	-	-	36	3.5%
Other specific types ^e (8680-8713,8720-8790, 8800-8921,8930-8936, 8950-9030,9040-9044, 9060-9110,9120-9136, 9150-9252,9260-9365, 9370-9373,9380-9539, 9540-9582)	50	0.3%	40	0.3%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	87	0.6%	81	0.6%	-	-	-	-	-	-	-	-
Total	15,743	100.0%	13,217	100.0%	1,666	100.0%	702	100.0%	71	100.0%	1,030	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

- Other specific types includes sarcomas and other soft tissue tumors.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 14.19

Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma (8010-8576)	16,497	97.1%	11,415	96.9%	1,926	98.0%	2,936	97.7%	113	93.4%	2,668	96.5%
Epidermoid carcinoma ^d (8170-8175)	12,961	76.3%	8,669	73.6%	1,615	82.2%	2,497	83.1%	95	78.5%	2,167	78.4%
Cholangiocarcinoma (8050,8140-8141, 8160-8161,8260,8440, 8480-8500,8570-8572)	2,510	14.8%	1,991	16.9%	199	10.1%	293	9.8%	-	-	353	12.8%
Intrahepatic cholangio- carcinoma (8160)	1,713	10.1%	1,350	11.5%	121	6.2%	219	7.3%	-	-	243	8.8%
Other (8050,8140-8141,8161, 8260,8440,8480-8500, 8570-8572)	797	4.7%	641	5.4%	78	4.0%	74	2.5%	-	-	110	4.0%
Other specific carcinomas ^e	370	2.2%	291	2.5%	40	2.0%	31	1.0%	-	-	37	1.3%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	322	1.9%	238	2.0%	38	1.9%	44	1.5%	-	-	46	1.7%
Hepatoblastoma (8970)	167	1.0%	134	1.1%	-	-	-	-	-	-	56	2.0%
Sarcoma ^f	153	0.9%	120	1.0%	-	-	21	0.7%	-	-	-	-
Haemangiosarcoma (9120-9133,9161)	95	0.6%	77	0.7%	-	-	-	-	-	-	-	-
Other sarcomas ^g	58	0.3%	43	0.4%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8969,8971-9030, 9060-9110,9260-9365,9380-9539)	46	0.3%	33	0.3%	-	-	-	-	-	-	16	0.6%
Unspecified (8000-8005)	123	0.7%	84	0.7%	-	-	24	0.8%	-	-	-	-
Total ^d	16,986	100.0%	11,786	100.0%	1,965	100.0%	3,004	100.0%	121	100.0%	2,765	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8177-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^g Sarcoma includes histologies 8680-8713, 8800-8921, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^h Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9135-9136, 9150-9160, 9170-9252, 9370-9373, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.25

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	197,766	98.9%	165,989	98.9%	19,930	99.1%	10,540	99.1%	675	98.3%	10,242	98.6%
Small cell (8041-8045)	28,076	14.0%	24,817	14.8%	2,151	10.7%	901	8.5%	127	18.5%	1,230	11.8%
Non-small cell ^d	169,690	84.9%	141,172	84.1%	17,779	88.4%	9,639	90.6%	548	79.8%	9,012	86.8%
Squamous and transitional cell (8051-8052,8070-8084, 8120-8131)	39,702	19.9%	33,175	19.8%	4,580	22.8%	1,657	15.6%	167	24.3%	1,806	17.4%
Adenocarcinoma (8050,8140-8149, 8160-8162,8190-8221, 8250-8263,8270-8280, 8290-8337,8350-8390, 8400-8560,8570-8576, 8940-8941)	73,764	36.9%	61,343	36.6%	6,932	34.5%	5,098	47.9%	169	24.6%	4,124	39.7%
Large cell (8011-8015)	7,066	3.5%	5,824	3.5%	860	4.3%	340	3.2%	21	3.1%	389	3.7%
Other non-small cell ^e	49,158	24.6%	40,830	24.3%	5,407	26.9%	2,544	23.9%	191	27.8%	2,693	25.9%
Sarcoma (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	344	0.2%	295	0.2%	28	0.1%	-	-	-	-	29	0.3%
Other specified types ^f (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	158	0.1%	133	0.1%	19	0.1%	-	-	-	-	-	-
Unspecified (8000-8005)	1,629	0.8%	1,400	0.8%	141	0.7%	76	0.7%	-	-	102	1.0%
Total	199,898	100.0%	167,818	100.0%	20,118	100.0%	10,636	100.0%	687	100.0%	10,385	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^f Includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas (8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671).

^g Other specific types includes melanomas.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.26

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Males by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	106,340	98.9%	87,963	98.9%	11,449	99.1%	6,241	99.1%	340	98.0%	5,796	98.7%
Small cell (8041-8045)	14,106	13.1%	12,271	13.8%	1,123	9.7%	613	9.7%	59	17.0%	699	11.9%
Non-small cell ^d	92,234	85.8%	75,692	85.1%	10,326	89.4%	5,628	89.4%	281	81.0%	5,097	86.8%
Squamous and transitional cell (8051-8052,8070-8084, 8120-8131)	25,268	23.5%	20,843	23.4%	3,011	26.1%	1,233	19.6%	95	27.4%	1,206	20.5%
Adenocarcinoma (8050,8140-8149, 8160-8162,8190-8221, 8250-8263,8270-8280, 8290-8337,8350-8390, 8400-8560,8570-8576, 8940-8941)	36,058	33.6%	29,650	33.3%	3,640	31.5%	2,575	40.9%	77	22.2%	2,111	36.0%
Large cell (8011-8015)	4,050	3.8%	3,300	3.7%	509	4.4%	225	3.6%	-	-	255	4.3%
Other non-small cell ^e	26,858	25.0%	21,899	24.6%	3,166	27.4%	1,595	25.3%	101	29.1%	1,525	26.0%
Sarcoma (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	203	0.2%	174	0.2%	18	0.2%	-	-	-	-	16	0.3%
Other specified types ^f (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	87	0.1%	74	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	844	0.8%	717	0.8%	77	0.7%	42	0.7%	-	-	53	0.9%
Total	107,475	100.0%	88,929	100.0%	11,552	100.0%	6,295	100.0%	347	100.0%	5,870	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^f Includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas (8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671).

^g Other specific types includes melanomas.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.27

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	91,426	98.9%	78,026	98.9%	8,481	99.0%	4,299	99.0%	335	98.5%	4,446	98.5%
Small cell (8041-8045)	13,970	15.1%	12,546	15.9%	1,028	12.0%	288	6.6%	68	20.0%	531	11.8%
Non-small cell ^d	77,456	83.8%	65,480	83.0%	7,453	87.0%	4,011	92.4%	267	78.5%	3,915	86.7%
Squamous and transitional cell (8051-8052,8070-8084, 8120-8131)	14,434	15.6%	12,332	15.6%	1,569	18.3%	424	9.8%	72	21.2%	600	13.3%
Adenocarcinoma (8050,8140-8149, 8160-8162,8190-8221, 8250-8263,8270-8280, 8290-8337,8350-8390, 8400-8560,8570-8576, 8940-8941)	37,706	40.8%	31,693	40.2%	3,292	38.4%	2,523	58.1%	92	27.1%	2,013	44.6%
Large cell (8011-8015)	3,016	3.3%	2,524	3.2%	351	4.1%	115	2.6%	-	-	134	3.0%
Other non-small cell ^e	22,300	24.1%	18,931	24.0%	2,241	26.2%	949	21.9%	90	26.5%	1,168	25.9%
Sarcoma (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	141	0.2%	121	0.2%	-	-	-	-	-	-	-	-
Other specified types ^f (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	71	0.1%	59	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	785	0.8%	683	0.9%	64	0.7%	34	0.8%	-	-	49	1.1%
Total	92,423	100.0%	78,889	100.0%	8,566	100.0%	4,341	100.0%	340	100.0%	4,515	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^f Includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas (8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671).

^g Other specific types includes melanomas.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 20.19

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	31,425	82.8%	2,678	95.2%	10,131	96.6%	926	20.8%	2,238	95.7%
Squamous cell carcinoma (8070-8078,8083-8084)	30,432	80.2%	2,594	92.2%	9,937	94.8%	877	19.7%	2,208	94.4%
Adenocarcinoma (8050,8140-8147,8160-8162,8180-8221, 8250-8507,8514,8520-8551,8560,8570-8574, 8576,8940-8941)	4,236	11.2%	95	3.4%	166	1.6%	2,862	64.2%	77	3.3%
Other specific carcinomas (8012-8015,8030-8046,8150-8155, 8170-8180,8230-8249,8508, 8510-8513,8561-8562,8575,8580-8671)	430	1.1%	-	-	21	0.2%	232	5.2%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,396	3.7%	-	-	115	1.1%	291	6.5%	-	-
Sarcoma and soft tissue (8680-8713,8800-8921,8990-8991,9040-9044, 9120-9136,9150-9252,9370-9373,9540-9582)	172	0.5%	-	-	22	0.2%	45	1.0%	-	-
Other specific types (8720-8790,8930-8936,8950-8983,9060-9110, 9260-9365,9380-9539)	190	0.5%	-	-	-	-	68	1.5%	-	-
Unspecified (8000-8005)	95	0.3%	-	-	18	0.2%	34	0.8%	-	-
Total	37,944	100.0%	2,813	100.0%	10,483	100.0%	4,458	100.0%	2,339	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b	4,283	79.9%	1,468	60.9%	6,755	96.9%	2,386	96.6%	560	87.4%
Squamous cell carcinoma	4,049	75.5%	1,201	49.9%	6,654	95.5%	2,359	95.5%	553	86.3%
Adenocarcinoma	886	16.5%	67	2.8%	47	0.7%	18	0.7%	18	2.8%
Other specific carcinomas	17	0.3%	77	3.2%	37	0.5%	23	0.9%	-	-
Unspecified, Carcinoma, NOS	57	1.1%	740	30.7%	108	1.5%	30	1.2%	35	5.5%
Sarcoma and soft tissue	31	0.6%	36	1.5%	-	-	-	-	-	-
Other specific types	72	1.3%	18	0.7%	-	-	-	-	-	-
Unspecified	-	-	-	-	-	-	-	-	-	-
Total	5,361	100.0%	2,409	100.0%	6,970	100.0%	2,470	100.0%	641	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.15

Cancer of the Ovary (Invasive)Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	22,480	92.4%	19,225	92.7%	1,496	89.9%	1,545	91.0%	103	92.8%	2,263	86.6%
Epidermoid carcinoma ^d (8051-8131)	186	0.8%	139	0.7%	-	-	28	1.6%	-	-	23	0.9%
Adenocarcinoma ^e	20,667	84.9%	17,735	85.5%	1,313	78.9%	1,432	84.3%	90	81.1%	2,036	77.9%
Adenocarcinoma, NOS (8140)	3,266	13.4%	2,757	13.3%	305	18.3%	177	10.4%	-	-	320	12.2%
Papillary adenocarcinoma, NOS (8050,8260)	687	2.8%	583	2.8%	67	4.0%	31	1.8%	-	-	55	2.1%
Clear cell adenocarcinoma (8310,9110)	1,229	5.0%	989	4.8%	47	2.8%	183	10.8%	-	-	101	3.9%
Endometrioid carcinoma (8380-8383,8570)	2,611	10.7%	2,227	10.7%	121	7.3%	234	13.8%	-	-	250	9.6%
Cystadenocarcinoma, NOS (8440,8450)	168	0.7%	133	0.6%	22	1.3%	-	-	-	-	17	0.7%
Serous cystadenocarcinoma (8441)	2,595	10.7%	2,243	10.8%	144	8.7%	184	10.8%	-	-	228	8.7%
Papillary serous cystadenocarcinoma (8460-8462)	7,462	30.7%	6,607	31.9%	439	26.4%	359	21.1%	30	27.0%	735	28.1%
Mucinous cystadenocarcinoma (8470-8473)	588	2.4%	477	2.3%	30	1.8%	67	3.9%	-	-	90	3.4%
Mucinous adenocarcinoma (8480,8482)	877	3.6%	707	3.4%	79	4.7%	79	4.7%	-	-	106	4.1%
Mucin-producing adenocarcinoma(8481)	92	0.4%	75	0.4%	-	-	-	-	-	-	-	-
Other	1,092	4.5%	937	4.5%	49	2.9%	101	5.9%	-	-	120	4.6%
Other specific carcinomas ^f	541	2.2%	421	2.0%	82	4.9%	32	1.9%	-	-	81	3.1%
Stromal cell tumor (8620-8631,8650)	308	1.3%	225	1.1%	61	3.7%	19	1.1%	-	-	49	1.9%
Other	190	0.8%	160	0.8%	18	1.1%	-	-	-	-	29	1.1%
Unspecified, "Carcinoma, NOS" (8010,8020-8022)	1,086	4.5%	930	4.5%	86	5.2%	53	3.1%	-	-	123	4.7%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941, 9110.

^f Other specific carcinomas includes histologies 8011-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8247-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.15 - continued

Cancer of the Ovary (Invasive)Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Females by Race

Histology ^a	<u>All Races</u>		<u>White</u>		<u>Black</u>		<u>Asian/Pacific Islander</u>		<u>American Indian/ Alaska Native^b</u>		<u>Hispanic^c</u>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	81	0.3%	61	0.3%	18	1.1%	-	-	-	-	-	-
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,595	6.6%	1,298	6.3%	134	8.1%	143	8.4%	-	-	303	11.6%
Mullerian mixed tumor (8950-8951,8980)	675	2.8%	586	2.8%	43	2.6%	42	2.5%	-	-	64	2.4%
Teratoma, malignant (9080-9085,9102)	336	1.4%	246	1.2%	36	2.2%	48	2.8%	-	-	101	3.9%
Other	584	2.4%	466	2.2%	55	3.3%	53	3.1%	-	-	138	5.3%
Unspecified (8000-8005)	182	0.7%	154	0.7%	16	1.0%	-	-	-	-	33	1.3%
Total ^d	24,338	100.0%	20,738	100.0%	1,664	100.0%	1,698	100.0%	111	100.0%	2,614	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22.19

Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	31,670	97.9%	25,895	97.8%	3,450	98.3%	2,064	98.3%	131	98.5%	2,985	97.7%
Epidermoid carcinoma ^d (8051-8131)	63	0.2%	46	0.2%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	27,580	85.3%	22,597	85.4%	2,978	84.8%	1,779	84.7%	116	87.2%	2,575	84.3%
Adenocarcinoma, NOS (8140)	22,206	68.7%	18,196	68.8%	2,454	69.9%	1,374	65.4%	100	75.2%	2,078	68.0%
Papillary adenocarcinoma, NOS (8260)	80	0.2%	65	0.2%	-	-	-	-	-	-	-	-
Mucinous adenocarcinoma (8480,8482)	964	3.0%	799	3.0%	83	2.4%	73	3.5%	-	-	79	2.6%
Mucin-producing adenocarcinoma (8481)	714	2.2%	579	2.2%	101	2.9%	31	1.5%	-	-	62	2.0%
Infiltrating duct carcinoma (8500-8503,8507,8514)	2,705	8.4%	2,201	8.3%	249	7.1%	232	11.0%	-	-	231	7.6%
Other adenocarcinoma (8050,8141-8147,8160-8162, 8180-8221,8250-8259, 8261-8479,8483-8499, 8504-8506,8520-8551, 8560,8570-8574,8576, 8940-8941)	911	2.8%	757	2.9%	84	2.4%	63	3.0%	-	-	113	3.7%
Other specific carcinomas ^f	1,812	5.6%	1,501	5.7%	185	5.3%	107	5.1%	-	-	178	5.8%
Islet cell carcinoma (8150-8155)	369	1.1%	312	1.2%	33	0.9%	19	0.9%	-	-	31	1.0%
Other carcinomas (8013-8015,8030-8046, 8179-8175,8230-8249, 8345,8510-8512, 8561-8562,8580-8671)	1,443	4.5%	1,189	4.5%	152	4.3%	88	4.2%	-	-	147	4.8%
Unspecified, "Carcinoma, NOS" (8010-8012, 8015-8022,8575)	2,215	6.8%	1,751	6.6%	277	7.9%	171	8.1%	-	-	230	7.5%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22-19 - continued

Cancer of the Pancreas (Invasive)Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9055, 9120-9134,9141-9340, 9540-9581)	30	0.1%	26	0.1%	-	-	-	-	-	-	-	-
Other specific types ^d (8720-8790,8930-8933, 8950-8982,9000-9030, 9060-9110,9350-9364, 9380-9513,9530-9539)	24	0.1%	22	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	616	1.9%	521	2.0%	55	1.6%	35	1.7%	-	-	63	2.1%
Total	32,340	100.0%	26,464	100.0%	3,510	100.0%	2,100	100.0%	133	100.0%	3,054	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.19

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	26,350	94.8%	19,134	95.1%	3,144	91.8%	3,728	95.7%	198	98.0%	4,306	96.9%
Epidermoid carcinoma ^d (8051-8131)	206	0.7%	155	0.8%	38	1.1%	-	-	-	-	16	0.4%
Squamous cell carcinoma (8070-8078,8083-8084)	199	0.7%	150	0.7%	37	1.1%	-	-	-	-	-	-
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941)	24,084	86.6%	17,359	86.3%	2,856	83.4%	3,575	91.8%	179	88.6%	3,943	88.7%
Adenocarcinoma, NOS (8140)	13,920	50.1%	10,353	51.5%	1,699	49.6%	1,700	43.6%	110	54.5%	1,959	44.1%
Adenocarcinoma, intestinal type (8144)	2,124	7.6%	1,249	6.2%	268	7.8%	579	14.9%	16	7.9%	355	8.0%
Carcinoma, diffuse type (8145)	754	2.7%	467	2.3%	78	2.3%	198	5.1%	-	-	157	3.5%
Linitus plastica (8142)	352	1.3%	265	1.3%	35	1.0%	49	1.3%	-	-	87	2.0%
Mucinous adenocarcinoma (8470-8473,8480,8482)	484	1.7%	351	1.7%	65	1.9%	61	1.6%	-	-	55	1.2%
Mucin-producing adenocarcinoma (8481)	291	1.0%	218	1.1%	46	1.3%	21	0.5%	-	-	36	0.8%
Signet ring adenocarcinoma (8490)	5,052	18.2%	3,681	18.3%	532	15.5%	780	20.0%	32	15.8%	1,097	24.7%
Other adenocarcinomas ^e	1,107	4.0%	775	3.9%	133	3.9%	187	4.8%	-	-	197	4.4%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	1,349	4.9%	1,088	5.4%	162	4.7%	64	1.6%	-	-	232	5.2%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	711	2.6%	532	2.6%	88	2.6%	77	2.0%	-	-	115	2.6%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.

Table XXIV-19 - continued

STOMACH CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	<u>All Races</u>		<u>White</u>		<u>Black</u>		<u>Asian/Pacific Islander</u>		<u>American Indian/ Alaska Native^b</u>		<u>Hispanic^c</u>	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	80	0.3%	63	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	1,228	4.4%	817	4.1%	250	7.3%	150	3.9%	-	-	105	2.4%
Unspecified (8000-8005)	142	0.5%	106	0.5%	20	0.6%	-	-	-	-	22	0.5%
Total ^d	27,800	100.0%	20,120	100.0%	3,426	100.0%	3,896	100.0%	202	100.0%	4,443	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 26.19

Cancer of the Thyroid (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2002-2006
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	36,212	99.8%	30,103	99.8%	2,117	99.7%	3,391	99.9%	151	100.0%	4,950	99.7%
Epidermoid carcinoma ^d (8051-8131)	46	0.1%	39	0.1%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	34,965	96.3%	29,054	96.3%	2,039	96.0%	3,299	97.2%	146	96.7%	4,796	96.6%
Papillary adenocarcinoma (8050,8260,8340-8344, 8350,8450)	30,964	85.3%	25,800	85.5%	1,688	79.5%	2,970	87.5%	129	85.4%	4,379	88.2%
Follicular carcinoma (8330-8332,8335)	2,381	6.6%	1,875	6.2%	237	11.2%	226	6.7%	-	-	247	5.0%
Oxyphilic (8290)	1,201	3.3%	1,031	3.4%	89	4.2%	65	1.9%	-	-	120	2.4%
Other specific carcinomas ^f	601	1.7%	526	1.7%	34	1.6%	30	0.9%	-	-	78	1.6%
Medullary carcinoma (8510,8511)	564	1.6%	495	1.6%	32	1.5%	27	0.8%	-	-	76	1.5%
Carcinoma, NOS (8004,8010-8012, 8020-8022,8030-8032)	600	1.7%	484	1.6%	43	2.0%	58	1.7%	-	-	69	1.4%
Anaplastic carcinoma (8004,8012,8020-8021, 8030-8032)	367	1.0%	297	1.0%	29	1.4%	36	1.1%	-	-	36	0.7%
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	-	-	-	-	-	-	-	-	-	-	-	-
Other specific types ^g	-	-	-	-	-	-	-	-	-	-	-	-
Unspecified (8000-8003,8005)	69	0.2%	57	0.2%	-	-	-	-	-	-	-	-
Total	36,295	100.0%	30,171	100.0%	2,124	100.0%	3,394	100.0%	151	100.0%	4,965	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Other specific carcinomas include histologies 8013-8015, 8030-8046, 8150-8155, 8170-8171, 8230-8249, 8510-8512, 8561-8562, 8575, 8580-8671.

^g Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.